Vericel Corporation (VCEL) caught a bid Tuesday while the broader market was taking a breather, and the reason is pretty straightforward: the company dropped some promising preliminary numbers for 2025 that suggest the business is humming along nicely.

The Numbers Look Pretty Good

Here's what Vericel is projecting for the full year 2025: total net revenue of approximately $276 million, with the star of the show being MACI, their cartilage repair product. MACI revenue hit $239.5 million, growing 23% in the fourth quarter alone. That's the kind of growth investors like to see.

The profitability story is solid too. The company expects to post GAAP net income for the second year running, backed by a hefty 74% gross margin. For a specialty biotech, those are respectable numbers that show the business model is working.

On the operational side, Vericel reported its highest-ever number of MACI implants and trained surgeons in a single quarter since launching the product. They now have over 900 surgeons trained on MACI, and they're planning to fire up commercial manufacturing at a new facility in 2026. The balance sheet looks clean too, with about $200 million in cash and investments and zero debt.

All this is happening while the S&P 500 and Nasdaq were slightly down and the Russell 2000 slipped 0.22%. So Vericel's move higher stands out as company-specific momentum rather than riding a market wave.

The Technical Picture Is Messy

If you're into chart reading, Vericel is sending mixed messages. The stock is trading 1.1% above its 20-day simple moving average and 5.3% above its 100-day SMA, which suggests some near-term strength. But it's sitting 0.7% below its 50-day SMA and 1.2% below its 200-day SMA, so the longer-term trend is murkier.

The bigger picture isn't pretty: the stock has dropped 36.77% over the past year. At $37.66, it's nowhere near its 52-week high of $63.00, which tells you this has been a rough ride despite Tuesday's pop.

The RSI sits at 45.54, firmly in neutral territory, meaning the stock isn't screaming overbought or oversold. Meanwhile, the MACD is above its signal line, suggesting some bullish momentum in the short term. Put it together and you've got conflicting signals that don't give a clear directional read.

Key levels to watch: resistance at $43.00 and support at $35.00.

What Analysts Are Expecting

Looking ahead to the next earnings report, analysts are penciling in earnings per share of 41 cents, up from 38 cents in the same quarter last year. Revenue estimates are coming in at $90.92 million, versus $75.38 million year-over-year.

The analyst consensus is a Buy rating with an average price target of $57.44, which implies substantial upside from current levels. That suggests Wall Street sees value here despite recent underperformance.

The Scorecard Isn't Great

Here's how Vericel stacks up across key metrics:

• Momentum: Weak (Score: 7.39/100) — The stock is underperforming relative to the market
• Quality: Neutral (Score: 55.81/100) — The balance sheet remains stable
• Value: Risk (Score: 11.04/100) — Trading at a steep premium relative to peers

The bottom line: The scores reveal a challenging environment for the stock. While the Quality metric shows some stability, the weak Momentum and Value scores suggest investors should tread carefully despite the promising preliminary results.

Price Action: Vericel shares were up 2.92% at $37.66 at the time of publication Tuesday, according to market data.